The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Specialised Subsets Of T Follicular Helper Cells In The Control Of Infection And Immune Pathology
Funder
National Health and Medical Research Council
Funding Amount
$593,888.00
Summary
Defective or uncontrolled production of antibodies leads to increased susceptibility to infection, allergies, and autoimmune diseases. A type of T cell called follicular helper (Tfh) has emerged as a key controller of both protective and pathologic antibody production. We have data suggesting there are specialised Tfh subsets, each controlling different stages and outcomes of antibody responses. Identifying how each subset is regulated and functions will provide novel targets to treat these chro ....Defective or uncontrolled production of antibodies leads to increased susceptibility to infection, allergies, and autoimmune diseases. A type of T cell called follicular helper (Tfh) has emerged as a key controller of both protective and pathologic antibody production. We have data suggesting there are specialised Tfh subsets, each controlling different stages and outcomes of antibody responses. Identifying how each subset is regulated and functions will provide novel targets to treat these chronic debilitating diseases.Read moreRead less
Regulating The Production Of High Affinity Antibody Forming Cells During The Germinal Centre Reaction.
Funder
National Health and Medical Research Council
Funding Amount
$376,980.00
Summary
In response to infection the body makes antibodies. These antibodies are important in helping clear the infection and keeping us healthy. What's more, the immune system 'remembers' these past infections. This means that when we are re-exposed to an infectious agent like measles virus, no disease develops. This is because the antibodies which cleared the infection initially, are still being made and prevent or neutralize the new infection or toxin. The continued production of these antibodies is ....In response to infection the body makes antibodies. These antibodies are important in helping clear the infection and keeping us healthy. What's more, the immune system 'remembers' these past infections. This means that when we are re-exposed to an infectious agent like measles virus, no disease develops. This is because the antibodies which cleared the infection initially, are still being made and prevent or neutralize the new infection or toxin. The continued production of these antibodies is therefore an important part of staying healthy. When we are vaccinated, we produce antibodies specific for the components of the vaccine. Some of these components are part of the real infectious agent. This means that when we encounter the real virus, we already have antibodies that prevent the virus from doing any damage. Booster immunizations are necessary to make sure we have high enough levels of these neutralizing antibodies. Being able to understand how these important antibodies are made is a central goal of this research project. We hope that by understanding how cells are durected in an immune response to become the kind of cells that secretes neutralizing antibodies, we will be able to make vaccines that work more efficiently, that require fewer booster injections and that give longer lasting protection. We also hope that we can better design vaccines so that those that currently don't work, can be made to do so.Read moreRead less
The MASTER Anaesthesia Trial (or Mulcentre Australian Study of Epidural Anaesthesia) is a large clinical experiment designed to determine whether using epidural techniques to control pain during and after surgery results in fewer complications after major surgery. The Trial involves a comparison of epidural methods, in which some of the anaesthetic and pain-killing drugs are injected into the space in the spinal column surrounding the sac that encloses the spinal cord, with conventional methods, ....The MASTER Anaesthesia Trial (or Mulcentre Australian Study of Epidural Anaesthesia) is a large clinical experiment designed to determine whether using epidural techniques to control pain during and after surgery results in fewer complications after major surgery. The Trial involves a comparison of epidural methods, in which some of the anaesthetic and pain-killing drugs are injected into the space in the spinal column surrounding the sac that encloses the spinal cord, with conventional methods, where the drugs are injected into a vein or muscle. Both approaches are well accepted in clinical practice, but it remains uncertain whether one is superior to the other. At present, nineteen hospitals in Australia, Hong Kong and Malaysia are contributing patients to the project, with others in New Zealand and Asia expected to join soon. If one method of anaesthesia and pain control is found to be significantly better than the other, in terms of avoiding complications, this would have obvious benefits to patients, but would also reduce lengths of stay in hospital and improve efficiency within the health system.Read moreRead less
The Role Of Linked Cytokines In T Helper Cell Differentiation
Funder
National Health and Medical Research Council
Funding Amount
$390,504.00
Summary
An important class of T cells known as T Follicular Helper cells (TFH) orchestrate the immune response so that we can produce antibodies to fight infection. The novel finding that our Lab made last year is that the molecule interleukin 21 (IL-21) is a growth factor for TFH. The findings we have made thus far could be used in a number of ways. For eg, IL-21could be used to expand numbers of TFH, using them to boost vaccination or natural defences against viruses, bacteria and tumour cells.
VITATOPS - A Randomised Controlled Trial Of Vitamins To Prevent Stroke
Funder
National Health and Medical Research Council
Funding Amount
$391,364.00
Summary
A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS ....A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS study arises from a large body of consistent, biologically plausible evidence linking homocysteine in a dose-dependent fashion to stroke and other types of vascular disease. A simple, non-toxic, and inexpensive intervention in the form of multivitamins (folate, B6 and B12) has been shown to be highly effective at reducing homocysteine levels, irrespective of the underlying cause. All patients who are referred to a neurologist or general physician in one of the collaborating centres within six months of a stroke or transient ischaemic attack are eligible for the trial. In total, treatment will continue for a period of between 1 and 5 years. During this time, patients will be closely monitored in order to record the occurrence of any vascular events (particularly strokes and heart attacks). Neither the study investigator nor the patient will know which treatment they are receiving (i.e. it is 'double blind'). The number of vascular events in the treatment groups will be compared at the end of the study in order to determine whether vitamin treatment is beneficial. This application is for five years of support to allow the investigators to move from the pilot phase of VITATOPS in Perth to begin recruitment to the definitive trial in other centres across Australia and New Zealand. This study may have a major impact on patient management. If vitamins prove to be effective, we may recommend vitamin supplementation to all of our stroke patients in the future.Read moreRead less
Multicentre Evaluation Of A Clinical Pathway For Chronic Cough In Children- Can Its Use Improve Clinical Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$971,362.00
Summary
Chronic cough is a common presenting symptom to doctors. It is associated with significant morbidity and may be a symptom of a serious underlying problem. This is especially pertinent to Aboriginal children. In this study we will examine the utility and efficacy of an evidence based clinical pathway for the management of chronic cough in Aboriginal and non-Aboriginal children. This study will contribute to clinical policy and improve clinical outcomes and early diagnosis of respiratory illnesses